Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

HA-Coated and Non-HA Threads for Midface Lifting and Nasolabial Fold Correction

29 de octubre de 2026 actualizado por: Aptos, LLC.

Evaluation of Safety and Effectiveness of APTOS Threads - Absorbable Surgical Sutures Excellence Product Line Models for Mid-face Suspension by Mini-Invasive Surgery to Temporarily Fixate the Cheek Sub-dermis in a Repositioned Site for the Treatment of Moderate to Severe Nasolabial Fold.

This randomized study compared absorbable facial lifting threads with and without a hyaluronic acid (HA) coating in 144 adults with moderate-to-severe nasolabial folds, the lines extending from the sides of the nose toward the corners of the mouth. Participants were randomly assigned in a 1:1 ratio to receive either HA-coated or non-HA threads.

Follow-up continued for six months. The main assessments evaluated adverse events through Day 30 and changes in nasolabial fold severity at Day 90. Independent evaluators assessed standardized photographs, and participants rated their aesthetic improvement and satisfaction. Additional assessments examined safety and maintenance of improvement through Day 180

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

144

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Batumi, Georgia, 6000
        • "Total Charm Piazza",15 Vakhtang Gorgasali Street
      • Tbilisi, Georgia, 0109
        • "Total Charm LTD", Orbeliani Str #18
      • Tbilisi, Georgia, 0162
        • "Total Charm Vake", 87B Zakaria Paliashvili Street

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

22 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male and female subjects, 22+ years of age.
  2. Subjects who desire cheek lifting to correct age-related wrinkles in the mid-face as recommended by the treating investigator.
  3. Subject received a rating, in each cheek, by Investigator of at least Grade 3 or Grade 4 for wrinkling of the NLF in the mid-face according to the WSRS.
  4. If a woman is of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), then she must have a confirmed negative urine pregnancy test result at screening. If treatment is not provided at the screening visit, a negative urine pregnancy test result is required within 7 days before treatment.
  5. If a woman of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile), subject confirms she will utilize at least one form of contraception throughout the duration of the study (6 months).
  6. Subjects who are able to understand the study requirements, including the obligation not to receive any other facial procedures or treatments affecting mid-face at any time during the study. These include procedures or treatments done at home or with a professional. Facial treatments include lasers, facial massages, and anything beyond common skincare routine.
  7. Subjects who are willing to participate in the study and to sign a witnessed/informed consent form.
  8. Subjects who are logistically able to present for all study visits and meet all study requirements.
  9. Subjects who are willing to complete a 30-day diary.
  10. Subjects who pass the pinprick and/or cotton swab facial nerve assessment

Exclusion Criteria:

  1. Abnormal rating in mid-face sensation, with inability to feel a 0.4 G monofilament or a cotton wisp at any site on the mid-face.
  2. Active acne or prominent acne scars in the treatment area.
  3. Active inflammatory or infectious conditions.
  4. Allergy or foreign body sensitivities to plastic biomaterials.
  5. Known bleeding disorder.
  6. Breast feeding, pregnant, or not on/willing to use contraception if of childbearing potential (not amenorrheic for the previous 24 months or not surgically sterile).
  7. Known collagen skin disorder.
  8. Pre-existing facial asymmetry.
  9. History of any device use on the mid-face in the prior 6 months (laser, Intense Pulsed Light [IPL], radiofrequency (RF), ultrasound, micro needling, micro needle RF, or cool based treatments).
  10. History of autoimmune or connective tissue disease.
  11. History of facelift, mid-face lift, lower facelift or neck lift that changes the facial structure and anchor points.
  12. History of fat transfer to the mid-face.
  13. History of injectable fillers other than temporary fillers such as HA or Radiesse to the mid-face at any time. Permanent and semi-permanent fillers are not allowed (Poly-L-lactic acids [PLLA], Sculptra).
  14. History of Kybella in the prior 6 months.
  15. History of facial trauma in the mid-face.
  16. History of facial surgical procedures.
  17. Inability to chew, puff cheek, or smile broadly.
  18. Metabolism irregularities.
  19. Receiving immunosuppressive therapy.
  20. Recent weight loss or intention to lose a significant amount of weight during the study period (2 body mass index [BMI] points).
  21. Subjects who have undergone cosmetic facial plastic surgery (with the exception of rhinoplasty or upper blepharoplasty) more than 2 years prior to enrollment, tissue grafting, or tissue lifting or augmentation with any permanent or semi-permanent filler.
  22. Subjects who have had temporary facial dermal filler injections below the orbital rim with HA-based fillers or Radiesse within 18 months, porcine-based collagen fillers within 24 months, or neuromodulator injections to the mid-face or lateral canthal lines, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months of entry in the study or who were planning to undergo any of these procedures at any time during the study.
  23. Subjects who have very thin skin in the mid-face region, who have a tendency to accumulate fluid in the lower eyelids, or who have large infraorbital fat pads (i.e., significant convexity or projection from the infraorbital fat pads).
  24. Subjects who have mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIVrelated disease.
  25. Subjects who are included to list of vulnerable populations (pediatric, pregnant, elderly individuals with visual or hearing impairments, mentally ill subjects).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: HA-Coated P(LA/CL) Lifting Threads

Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads coated with hyaluronic acid in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence HA, Visage Excellence Soft HA, or Nano Excellence HA threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation.

The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] and coated with non-animal-derived, non-cross-linked, medium-molecular-weight sodium hyaluronate. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence HA (190 mm), Visage Excellence Soft HA (100 mm), and Nano Excellence HA (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning.

Experimental: Non-HA-Coated P(LA/CL) Lifting Threads

Participants received absorbable poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] lifting threads without hyaluronic acid coating in a single bilateral midface procedure under local anesthesia. Five threads were placed subcutaneously on each side of the face. Visage Excellence, Visage Excellence Soft, or Nano Excellence threads were selected according to the planned implantation trajectory. Participants were followed for six months after implantation.

The device consists of absorbable, multibarbed monofilament threads made from poly(L-lactide-co-ε-caprolactone) [P(LA/CL)] without hyaluronic acid coating. Manufactured by Aptos LLC, Georgia, the models used were Visage Excellence (190 mm), Visage Excellence Soft (100 mm), and Nano Excellence (80 mm). All models had the same number of barbs despite their different lengths and were supplied preloaded in cannulas for subcutaneous tissue repositioning.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Incidence of device and procedure related serious adverse events by Day 30 (Month 1) after the implantation procedure.
Periodo de tiempo: From implantation through Day 30.
From implantation through Day 30.
Reduction in NLF severity at Day 90 (Month 3) after the implantation procedure in comparison with baseline grading, as assessed by blinded evaluators using the Wrinkles Severity Rating Scale (WSRS).
Periodo de tiempo: Baseline and Day 90 after implantation
Baseline and Day 90 after implantation

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Incidence of all adverse events after implantation of threads throughout the whole study.
Periodo de tiempo: through Day 180 [Month 6] after the implantation procedure
through Day 180 [Month 6] after the implantation procedure
Incidence of early recovery symptoms related to the treatment (threads implantation) among adverse events reported by both patients and treating physician(s)
Periodo de tiempo: Up to Day 14 after the implantation procedure.
Up to Day 14 after the implantation procedure.
Observed values and change from baseline in WSRS
Periodo de tiempo: On Day 30 and Day 180.
On Day 30 and Day 180.
The proportion of subjects with improvement of ≥1 WSRS score at each visit
Periodo de tiempo: Days 30, 90, and 180 after implantation.
Days 30, 90, and 180 after implantation.
Mean GAIS value assessed by blinded evaluators with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
Periodo de tiempo: On Day 30, Day 90, and Day 180
On Day 30, Day 90, and Day 180
Mean GAIS value assessed by subject with frequency of each grade and sum of improved subjects (excellent, very much improved, improved)
Periodo de tiempo: Days 30, 90, and 180 after implantation.
Days 30, 90, and 180 after implantation.
Patient satisfaction with the procedure outcome assessed using the mean total Face-QTM Satisfaction with Outcome score.
Periodo de tiempo: At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.
At Day 30 (Month 1), Day 90 (Month 3), and Day 180 (Month 6) after the implantation procedure.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Silla de estudio: Anna Kadzhaya, MD, Aptos LLC, Tbilisi, Georgia.15 Givi Amilakhvari Street

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de junio de 2024

Finalización primaria (Actual)

13 de diciembre de 2024

Finalización del estudio (Actual)

1 de marzo de 2025

Fechas de registro del estudio

Enviado por primera vez

29 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

29 de octubre de 2026

Publicado por primera vez (Actual)

4 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Excellence - 001

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir